UPDATE 1-Biogen revenue climbs; Spinraza, Tecfidera sales miss

April 24 (Reuters) - Drug developer Biogen Inc reported a 11.4 percent rise in quarterly revenue as sales of key drugs Tecfidera and Spinraza climbed, albeit at a weaker-than-expected pace.